Clinical Trial Update: Safety and Efficacy Study of Imiquimod 5% Cream Applied 3x Per Week for 8 or 12 Weeks in Low Risk Nodular Basal Cell Carcinoma [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating the safety and efficacy of imiquimod 5% cream applied three times weekly for 8 or 12 weeks in low-risk nodular basal cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Basal Cell Carcinoma

Drugs mentioned

• Imiquimod 5% cream (Imiquimod)

Snippet

Sponsor: University Hospital Tuebingen | Conditions: Carcinoma, Basal Cell | Phase 4 | Status: COMPLETED